GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells $21,582.00 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 275 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total value of $21,582.00. Following the transaction, the chief financial officer now owns 2,950 shares in the company, valued at approximately $231,516. This represents a 8.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The stock was sold at an average price of $93.82, for a total value of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The shares were sold at an average price of $76.04, for a total value of $108,737.20.
• On Monday, December 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total value of $286,124.00.
• On Monday, December 9th, Kevin Feeley sold 1,137 shares of GeneDx stock. The shares were sold at an average price of $76.37, for a total value of $86,832.69.
• On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The shares were sold at an average price of $78.39, for a total transaction of $20,616.57.
• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The stock was sold at an average price of $73.76, for a total transaction of $886,521.44.

GeneDx Price Performance

Shares of NASDAQ:WGS traded down $3.01 during midday trading on Friday, reaching $74.85. 393,012 shares of the company’s stock were exchanged, compared to its average volume of 865,986. GeneDx Holdings Corp. has a 12 month low of $3.62 and a 12 month high of $98.87. The firm has a market capitalization of $2.06 billion, a PE ratio of -24.07 and a beta of 2.02. The company’s 50 day simple moving average is $78.37 and its two-hundred day simple moving average is $57.69. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.21) by $0.25. The company had revenue of $76.90 million during the quarter, compared to analysts’ expectations of $64.98 million. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. GeneDx’s revenue was up 44.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.82) EPS. Equities research analysts expect that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. MCF Advisors LLC lifted its stake in GeneDx by 107.7% in the fourth quarter. MCF Advisors LLC now owns 351 shares of the company’s stock valued at $27,000 after buying an additional 182 shares in the last quarter. Global Retirement Partners LLC bought a new stake in shares of GeneDx in the fourth quarter worth $28,000. CWM LLC bought a new stake in shares of GeneDx in the third quarter worth $89,000. Evolution Wealth Advisors LLC bought a new stake in GeneDx during the fourth quarter worth $202,000. Finally, PFG Investments LLC bought a new stake in GeneDx during the fourth quarter worth $252,000. Institutional investors own 61.72% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on WGS. TD Cowen boosted their price objective on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday, January 7th. Wells Fargo & Company upped their target price on shares of GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 30th. The Goldman Sachs Group increased their price objective on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Finally, Craig Hallum increased their price objective on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $70.67.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.